Ocular symptoms in association with antiphospholipid antibodies

Leo-Kottler, Beate; Klein, Reinhild; Berg, Peter A.; Zrenner, Eberhart

doi:10.1007/s004170050138

Cited by 29 publications

(14 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is also some evidence for its contribution to arterial occlusive disease [14]. While Salomon et al [15] did not find LA to be a risk factor for anterior ischemic optic neuropathy (AION), others report an association between AION and LA [16, 17]. LA has also been found to be increased in patients with amaurosis fugax (AF) [18] as well as in central retinal artery occlusion (CRAO) and retinal arterial branch occlusion [19].…”

Section: Introductionmentioning

confidence: 99%

Antiphospholipid Antibodies in Ocular Arterial and Venous Occlusive Disease

et al. 2006

View full text Add to dashboard Cite

Purpose: It was the aim of this study to evaluate antiphospholipid antibodies (APA), i.e. lupus anticoagulants (LA) and anticardiolipin (ACA) IgG and IgM, in ophthalmic occlusive disease. Methods: Over a 3.5-year period, APA were evaluated in 368 patients. Results: Eighty-six patients (23.4%), compared to 5% in the general population, tested positive for APA. APA did not differ significantly between patients with venous (20.6%) or arterial (25.5%) occlusive disease. This included 93 patients with central retinal vein occlusion (18% APA positive), 67 with retinal branch vein occlusion (24% APA positive), 41 with central retinal artery occlusion (22% APA positive), 53 with retinal branch artery occlusion (32% APA positive), 71 with anterior ischemic optic neuropathy (23% APA positive), 12 with posterior ischemic optic neuropathy (33% APA positive) and 31 patients with amaurosis fugax (23% APA positive). Excluding patients with accepted main risk factors, APA were positive in 15.3% of 85 patients. Conclusion: The high APA prevalence confirms its relevance in ocular occlusive disorders.

show abstract

Section: Introductionmentioning

confidence: 99%

Antiphospholipid Antibodies in Ocular Arterial and Venous Occlusive Disease

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Patients often present with visual symptoms including monocular or binocular blurring of vision, amaurosis fugax, transient scotoma and visual field defect 4 5 7 13 18 22. Other symptoms cited in the literature include dry eye symptoms, redness and pain 13 19 22.…”

Section: Clinical Featuresmentioning

confidence: 99%

“…Retinal findings include venous tortuosity, dilation and flame haemorrhages 5 13 18. Classically, APS has been associated with unilateral and bilateral central retinal vein occlusion (CRVO), central retinal artery occlusion (CRAO), branched retinal vein occlusion (BRVO) and branched retinal artery occlusion (BRAO) 5 25–37.…”

Section: Clinical Featuresmentioning

confidence: 99%

Ocular manifestations of the antiphospholipid syndrome

Utz

Tang

2010

British Journal of Ophthalmology

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS) is an autoimmune disease characterised by a heterogenous group of antibodies directed against negatively charged phospholipids including antiphospholipid antibodies (aPL), anticardiolipin antibodies (aCL) and β-2 glycoprotein I (aβ-2-GP1). The major features of this disorder include arterial and venous thrombosis and recurrent fetal loss. The vasculature of the eye is frequently involved and may be the presenting manifestation. A diagnosis of APS should be considered in a young patients without traditional thromboembolic risk factors presenting with ocular vaso-occlusive disease. Management of these patients involves a team-approach with a haematologist/oncologist or rheumatologist to manage the coagulation status of these patients to prevent further systemic vascular occlusions.

show abstract

“…12 The altered hematologic parameters in ION include increased hematocrit, fibrinogen, blood viscosity, and aggregation indices often higher than normal subjects. 13 Hyperhomocysteinemia constitutes a risk factor for cardiac vaso-occlusive disease.…”

Section: Seminars In Ophthalmologymentioning

confidence: 99%